PMID- 37154218
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231114
IS  - 1744-8417 (Electronic)
IS  - 1744-6651 (Linking)
VI  - 18
IP  - 4
DP  - 2023 Sep-Nov
TI  - The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative 
      review.
PG  - 271-282
LID - 10.1080/17446651.2023.2210673 [doi]
AB  - INTRODUCTION: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), 
      the most recent oral antihyperglycaemic agents, provide a cardiorenal protection, 
      an effect independent of their glucose-lowering potency. AREAS COVERED: The 
      antihyperglycaemic potency of SGLT2is was compared with that of dipeptidyl 
      peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, especially 
      when added to metformin monotherapy. Main results of cardiovascular/renal outcome 
      trials with SGLT2is were summarized in different populations: patients with type 
      2 diabetes mellitus (T2DM) with or without established cardiovascular disease, 
      patients (with or without T2DM) with heart failure (with reduced or preserved 
      left ventricular ejection fraction) and in patients (with or without T2DM) with 
      chronic kidney disease (CKD, including stage 4). Original papers and 
      meta-analyses of these different trials have consistently reported a reduction in 
      hospitalization for heart failure (alone or combined with cardiovascular 
      mortality) and a reduced progression of CKD, with an overall good safety profile. 
      EXPERT OPINION: Global use of SGLT2is has increased over time but remains 
      suboptimal despite clinically relevant cardiovascular and renal protection, 
      particularly in patients most likely to benefit. SGLT2is has proven both positive 
      benefit-risk balance and cost-effectiveness in at risk patients. New prospects 
      are expected in other complications, i.e. metabolic-associated fatty liver 
      disease and neurodegenerative disorders.
FAU - Scheen, Andre J
AU  - Scheen AJ
AD  - Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, 
      CHU Liege, Liege, Belgium.
AD  - Division of Clinical Pharmacology, Centre for Interdisciplinary Research on 
      Medicines (CIRM), Liege University, Liege, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230508
PL  - England
TA  - Expert Rev Endocrinol Metab
JT  - Expert review of endocrinology & metabolism
JID - 101278293
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Sodium-Glucose Transporter 2 Inhibitors/pharmacology/therapeutic use
MH  - Stroke Volume
MH  - Ventricular Function, Left
MH  - *Renal Insufficiency, Chronic/complications/drug therapy
MH  - *Heart Failure/drug therapy
MH  - Glucose
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - SGLT2 inhibitor
OT  - cardiovascular mortality
OT  - chronic kidney disease
OT  - gliflozin
OT  - guidelines
OT  - heart failure
EDAT- 2023/05/08 13:41
MHDA- 2023/05/08 13:42
CRDT- 2023/05/08 06:34
PHST- 2023/05/08 13:42 [medline]
PHST- 2023/05/08 13:41 [pubmed]
PHST- 2023/05/08 06:34 [entrez]
AID - 10.1080/17446651.2023.2210673 [doi]
PST - ppublish
SO  - Expert Rev Endocrinol Metab. 2023 Sep-Nov;18(4):271-282. doi: 
      10.1080/17446651.2023.2210673. Epub 2023 May 8.